2024
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Sanft T, Wong J, O'Neal B, Siuliukina N, Jankowitz R, Pegram M, Fox J, Zhang Y, Treuner K, O'Shaughnessy J. Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 99-107. PMID: 38437792, DOI: 10.6004/jnccn.2023.7087.Peer-Reviewed Original ResearchBenefit of endocrine therapyBreast Cancer IndexPatient satisfactionEndocrine therapyRegistry studyReduce patient concernsPhysician decision-makingClinical practiceEarly-stage breast cancerIncrease physician confidenceCancer indexHormone receptor-positive early-stage breast cancerDrug safetyPhysician recommendationMedication adherencePhysician confidenceWilcoxon signed rank testPatient concernsClinical careDecision-makingPatient preferencesLate distant recurrencePhysiciansTest questionnaireLong-term outcomes
2023
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Foldi J, Tsagianni A, Salganik M, Schnabel C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer 2023, 23: 606. PMID: 37391697, PMCID: PMC10314405, DOI: 10.1186/s12885-023-11104-w.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerEndocrine therapyBreast cancerLate breast cancer recurrenceExtended endocrine therapyNon-persistence ratesIntolerable side effectsBone density scanBreast cancer recurrenceHigher likelihoodRate of persistenceElectronic health recordsConclusionsIn patientsMedication persistenceTreatment persistenceLow patientsMetastatic recurrenceCancer recurrenceCommon reasonSide effectsPatientsStage I
2022
The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.
O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.Peer-Reviewed Original ResearchBreast Cancer IndexExtended endocrine therapyLate distant recurrenceBreast cancer patientsRegistry studyEndocrine therapyDistant recurrenceClinicopathological factorsMedication adherenceCancer patientsHigh riskLower riskHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsEarly-stage breast cancer patientsNCCN Clinical Practice GuidelinesLong-term clinical outcomesPositive breast cancer patientsAssociated clinicopathological factorsAdjuvant endocrine therapyNode-negative patientsNode-positive patientsPrognostic risk groupsClinical practice guidelinesRoutine clinical care0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment
Hwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment. Sleep 2022, 45: a259-a260. DOI: 10.1093/sleep/zsac079.587.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexPoor sleep healthSleep healthBreast cancerPsychosocial dataGlobal Pittsburgh Sleep Quality IndexYoung womenCancer treatmentRoutine survivorship careSevere night sweatsSleep Quality IndexBreast cancer treatmentCross-sectional studyPrimary cancer treatmentSignificant clinical problemYears of ageQuality of lifeNon-Hispanic whitesWarrants further investigationEndocrine therapyGeneral Functioning subscaleNight sweatsSurvivorship careClinical factorsCancer survivors
2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2020
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. DOI: 10.1200/jco.2020.38.15_suppl.527.Peer-Reviewed Original ResearchLate distant recurrenceAdjuvant endocrine therapyEndocrine therapyDistant recurrenceDXA scansBreast cancerHigh riskStage IEarly-stage hormone receptorExtended endocrine therapyIntolerable side effectsOsteopenia/osteoporosisPositive breast cancerRate of adherenceSerious adverse effectsBreast cancer recurrenceMajority of ptsHigher likelihoodElectronic health recordsLocal recurrenceMedian ageLate recurrenceMetastatic recurrenceTumor characteristicsMedication adherence
2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
Bardia A, Hurvitz S, DeMichele A, Clark A, Zelnak A, Yardley D, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Caria N, Purkayastha D, Mistry A, Moulder S. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. Journal Of Clinical Oncology 2019, 37: 1016-1016. DOI: 10.1200/jco.2019.37.15_suppl.1016.Peer-Reviewed Original ResearchEndocrine therapyTriplet therapyMedian PFSClinical benefitCDK4/6 inhibitorsPrimary efficacy end pointSingle-agent endocrine therapyPhase I/IIPhase IMost common AEsShorter median PFSSubsequent-line therapyEfficacy end pointOpen-label trialLines of therapyEfficacy/safetyEntire patient populationCorrelation of biomarkersTumor genomic profileCommon AEsPostmenopausal womenTriplet regimenOptimal regimenWeek 24Investigator assessmentA prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.Peer-Reviewed Original Research
2017
Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Aktas B, Brufsky A, Pusztai L, Gustavsen G, Van Londen G. Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET). Journal Of Clinical Oncology 2017, 35: 25-25. DOI: 10.1200/jco.2017.35.8_suppl.25.Peer-Reviewed Original ResearchHormone-responsive breast cancerBreast Cancer IndexAdjuvant endocrine therapyEndocrine therapyCancer indexBreast cancerEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerYale Cancer CenterReal-world cohortResponsive breast cancerPopulation of patientsGene expression-based testsPositive breast cancerHealth economic impactHealth economic analysisLikelihood of benefitPittsburgh Medical CenterNet cost savingsYr of treatmentGross cost savingsAdverse eventsExtended therapyLate recurrence
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original Research
2014
Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.Peer-Reviewed Original Research